AI Terminal
DIACEUTICS PLC
AGM Information • May 26, 2022
7596_dva_2022-05-26_fc6bdfe9-eb75-44e4-9585-eacbca124f53.html
AGM Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 9743M
Diaceutics PLC
26 May 2022
26 May 2022
Diaceutics PLC
("Diaceutics" or "the Company")
Results of Annual General Meeting
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, is pleased to announce that all resolutions proposed at its Annual General Meeting held earlier today, were duly passed by a show of hands.
The proxy votes received from shareholders in respect of each resolution are set out below and are available on the Company's website, www.diaceutics.com.
| Resolution | For (excluding at Chair's discretion) | Against | Total votes cast | Withheld | |||
| Number of votes | % | Number of votes | % | Number of votes | |||
| 1 | Ordinary resolution to receive and consider the 2021 Financial Statements | 62,700,675 | 100.00% | 0 | 0.00% | 62,700,675 | Nil |
| 2 | Ordinary resolution to approve the directors' remuneration report | 62,693,325 | 99.99% | 7,350 | 0.01% | 62,700,675 | Nil |
| 3 | Ordinary resolution to re-elect Nick Roberts as a director | 62,700,675 | 100.00% | 0 | 0.00% | 62,700,675 | Nil |
| 4 | Ordinary resolution to re-elect Charles Hindson as a director | 61,651,904 | 98.32% | 900,000 | 1.44% | 62,551,904 | Nil |
| 5 | Ordinary resolution to re-appoint PricewaterhouseCoopers LLP as auditors | 62,550,243 | 99.75% | 1,661 | 0.01% | 62,551,904 | Nil |
| 6 | Ordinary resolution to authorise the directors to determine the remuneration of the auditors | 62,700,675 | 100.00% | 0 | 0.00% | 62,700,675 | Nil |
| 7 | Ordinary resolution to authorise the directors to allot shares | 62,699,175 | 100.00% | 0 | 0.00% | 62,700,675 | 1,500 |
| 8 | Special resolution to authorise the directors to disapply pre-emption rights | 62,697,164 | 99.9% | 2,011 | 0.01% | 62,699,175 | 1,500 |
| 9 | Special resolution to authorise the directors to purchase own shares | 60,606,084 | 99.99% | 8,661 | 0.01% | 62,614,745 | 2,085,930 |
Enquiries:
| Diaceutics PLC | |
| Peter Keeling, Chief Executive Officer | Via Alma PR |
| Nick Roberts, Chief Financial Officer | |
| Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
| Ben Maddison, Stewart Wallace, Nick Adams | |
| Alma PR | Tel: +44(0)20 3405 0205 |
| Caroline Forde, Kieran Breheny, Matthew Young | [email protected] |
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGKZGZKFVKGZZM